Personalis, Inc.
PSNL Nasdaq Services-Medical Laboratories Financials FY2017βFY2025
What Personalis, Inc. does
No business description yet.
- Legal name
- Personalis, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Feb 26, 2026
- Accession Β· CIK
- 0001193125-26-076615
0001527753
Revenue and margins
Personalis, Inc. had $69.6M of revenue in fiscal 2025, down 17.7% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was β$79.5M in fiscal 2025, β114.1% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Personalis, Inc. returned β to shareholders in fiscal 2025. The diluted share count rose 50.6%.
Balance sheet
Cash, debt and the ratios that show how comfortably Personalis, Inc. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $287M | $168M | $114M | $185M | $240M |
| Interest coverage | β355.2x | β574.8x | β999.4x | β2,844.5x | β429.5x |
| Current ratio | 10.2x | 6.0x | 3.1x | 6.5x | 6.8x |
| Quick ratio | 10.2x | 6.0x | 3.1x | 6.5x | 6.8x |
| Total assets | $397M | $293M | $225M | $270M | $334M |
| Total liabilities | $86.2M | $74.6M | $95.7M | $67.3M | $73.0M |
| Shareholders' equity | $310M | $218M | $129M | $203M | $261M |
| Net debt (β = net cash) | β | β | β | β | β |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 5 | 4 / 8 | 1 / 8 | 3 / 8 | 2 / 8 | 3 / 8 | 4 / 8 | 3 / 8 |
| Accruals ratio | β | β61.1% | β7.1% | 0.7% | 1.7% | β12.5% | β20.1% | β14.6% | β2.1% |
| Altman Z'' | β | β17.62 | 2.08 | 5.35 | 5.39 | 0.14 | β5.75 | β0.99 | 0.31 |
9 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | $9.4M | $37.8M | $65.2M | $78.6M | $85.5M | $65.0M | $73.5M | $84.6M | $69.6M |
| Gross profit | β$2.3M | $11.8M | $22.1M | $20.1M | $31.7M | $13.4M | $18.2M | $26.8M | $15.8M |
| Research and development | $9.9M | $14.3M | $22.4M | $28.6M | $49.3M | $64.9M | $64.8M | $48.9M | $50.3M |
| Operating income | β$22.2M | β$13.8M | β$22.4M | β$42.1M | β$65.4M | β$116M | β$110M | β$68.3M | β$88.1M |
| Interest expense | $1.3M | $1.9M | $1.1M | $0.0M | $0.2M | $0.2M | $0.1M | $0.0M | $0.2M |
| Pretax income | β$23.6M | β$19.9M | β$25.1M | β$41.2M | β$65.2M | β$113M | β$108M | β$81.3M | β$81.2M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.1M | $0.0M | $0.0M | $0.1M | $0.0M | $0.0M |
| Net income | β$23.6M | β$19.9M | β$25.1M | β$41.3M | β$65.2M | β$113M | β$108M | β$81.3M | β$81.3M |
| Net income to common | β$23.6M | β$19.9M | β$25.1M | β$41.3M | β | β | β | β | β |
| Diluted EPS | β$7.78 | β$6.49 | β$1.39 | β$1.20 | β$1.49 | β$2.48 | β$2.25 | β$1.37 | β$0.91 |
| Diluted shares | 0.00B | 0.00B | 0.02B | 0.03B | 0.04B | 0.05B | 0.05B | 0.06B | 0.09B |
| Cash flow | |||||||||
| Cash from operations | $0.3M | $5.6M | β$18.1M | β$42.7M | β$70.8M | β$70.2M | β$56.3M | β$45.2M | β$74.9M |
| Capital expenditure | $5.2M | $7.9M | $8.4M | $3.2M | $11.1M | $49.9M | $10.9M | $1.6M | $4.5M |
| Free cash flow | β$4.9M | β$2.3M | β$26.5M | β$45.9M | β$81.9M | β$120M | β$67.2M | β$46.8M | β$79.5M |
| Depreciation and amortization | $1.2M | $3.1M | $4.7M | $5.8M | $6.0M | $8.4M | $11.3M | $10.9M | $10.0M |
| Stock-based compensation | $0.8M | $1.3M | $4.9M | $8.2M | $14.4M | $19.4M | $14.1M | $10.7M | $9.4M |
| Balance sheet | |||||||||
| Cash and short-term investments | $22.6M | $19.7M | $128M | $203M | $287M | $168M | $114M | $185M | $240M |
| Total debt | β | $10.0M | β | β | β | β | β | β | β |
| Finance lease liabilities | β | β | β | β | β | β | β | β | $3.2M |
| Current assets | β | $29.6M | $140M | $221M | $318M | $200M | $147M | $203M | $268M |
| Current liabilities | β | $57.9M | $50.0M | $40.6M | $31.3M | $33.1M | $47.2M | $31.1M | $39.6M |
| Property and equipment, net | β | $11.5M | $14.1M | $11.8M | $19.7M | $61.9M | $57.4M | $48.3M | $44.8M |
| Total assets | β | $41.7M | $157M | $245M | $397M | $293M | $225M | $270M | $334M |
| Total liabilities | β | $58.7M | $50.6M | $49.9M | $86.2M | $74.6M | $95.7M | $67.3M | $73.0M |
| Shareholders' equity | β$92.6M | β$106M | $107M | $195M | $310M | $218M | $129M | $203M | $261M |
| Margins | |||||||||
| Gross margin | β24.9% | 31.3% | 33.9% | 25.6% | 37.0% | 20.5% | 24.8% | 31.7% | 22.7% |
| Operating margin | β236.0% | β36.5% | β34.4% | β53.6% | β76.4% | β177.6% | β149.6% | β80.7% | β126.4% |
| EBITDA margin | β223.0% | β28.3% | β27.1% | β46.3% | β69.4% | β164.6% | β134.2% | β67.8% | β112.0% |
| Net margin | β251.2% | β52.6% | β38.5% | β52.5% | β76.3% | β174.2% | β147.4% | β96.1% | β116.7% |
| FCF margin | β51.8% | β6.0% | β40.6% | β58.4% | β95.8% | β184.7% | β91.4% | β55.3% | β114.1% |
| Returns | |||||||||
| Return on capital employed | β | 85.1% | β20.9% | β20.6% | β17.9% | β44.5% | β61.8% | β28.5% | β29.9% |
| Return on equity | β | β | β16,611.9% | β27.4% | β25.8% | β42.9% | β62.3% | β48.9% | β35.0% |
| Return on assets | β | β47.7% | β25.2% | β20.5% | β20.3% | β32.9% | β41.8% | β32.8% | β26.9% |
| Return on tangible equity | β | β | β23.5% | β21.2% | β21.0% | β51.9% | β83.7% | β40.0% | β31.1% |
| Growth | |||||||||
| Revenue growth | β | 302.2% | 72.6% | 20.6% | 8.7% | β23.9% | 13.0% | 15.2% | β17.7% |
| Share count change | β | 1.0% | 488.0% | 90.8% | 27.7% | 4.1% | 5.4% | 23.0% | 50.6% |
| Financial health | |||||||||
| Interest coverage | β17.0x | β7.3x | β19.8x | β21,073.0x | β355.2x | β574.8x | β999.4x | β2,844.5x | β429.5x |
| Current ratio | β | 0.5x | 2.8x | 5.4x | 10.2x | 6.0x | 3.1x | 6.5x | 6.8x |
| Quick ratio | β | 0.5x | 2.8x | 5.4x | 10.2x | 6.0x | 3.1x | 6.5x | 6.8x |
| Capital allocation | |||||||||
| Capex / revenue | 54.9% | 20.8% | 12.9% | 4.1% | 13.0% | 76.7% | 14.8% | 1.9% | 6.5% |
| Stock comp / revenue | 8.0% | 3.5% | 7.5% | 10.5% | 16.8% | 29.9% | 19.1% | 12.6% | 13.5% |
| Quality scores | |||||||||
| Piotroski F-score | β | β | 4.0 | 1.0 | 3.0 | 2.0 | 3.0 | 4.0 | 3.0 |
| Altman Z'' | β | β17.6 | 2.1 | 5.3 | 5.4 | 0.1 | β5.7 | β1.0 | 0.3 |
| Accruals ratio | β | β61.1% | β7.1% | 0.7% | 1.7% | β12.5% | β20.1% | β14.6% | β2.1% |
Source: SEC EDGAR XBRL filings (CIK 0001527753). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.